Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 185,080 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Ulcerative Colitis
Interventions: Hydroxocobalamin with Butyrate, Placebo with Butyrate; Drug
Lead sponsor: Joshua Korzenik; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions: Abatacept, placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 15 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more

Conditions: Obstructive Sleep Apnea
Interventions: Respiratory muscle strength training, Sham respiratory muscle strength training; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy
Interventions: Denifanstat, Resmetirom; Drug
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Multiple Sclerosis, Relapse
Interventions: Blood samples and processing; Diagnostic Test
Lead sponsor: Regina Elena Cancer Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Wolman Disease, Cholesterol Ester Storage Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Interventions: There are no interventions in this study.; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Prostate Cancer
Interventions: docetaxel, sorafenib tosylate; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Smallpox
Interventions: ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 28 Years and older
Enrollment: 357 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 3
States / cities: Lenexa, Kansas • Springfield, Missouri • Pawtucket, Rhode Island

Conditions: Breast Cancer
Interventions: esterified estrogens; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer, Tumors, Neoplasm, Malignancy
Interventions: BMS-986226, Nivolumab, Ipilimumab, Tetanus Vaccine; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Boston, Massachusetts • St Louis, Missouri • Hackensack, New Jersey + 2 more

Conditions: Photodamage
Interventions: Assess the safety and efficacy of light-laser therapy using the Harmony XL and Dye-VL (500-600nm), Q-Switched 1064nm, Er:YAG 2940nm modules in combination .; Device
Lead sponsor: Alma Lasers Inc.; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Edina, Minnesota

Conditions: Glabellar Frown Lines
Interventions: Botulinum toxin, Type A, 0.9% sterile, unpreserved saline; Biological · Other
Lead sponsor: Evolus, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Multivessel Pulmonary Vein Stenosis
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Epilepsy, Brain Tumor, Speech
Interventions: Speech Tasks; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 7 Years to 18 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis and Saint Paul, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Metformin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Healthy
Interventions: Ondansetron, Zofran®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Optic, Atrophy, Hereditary, Leber
Interventions: GS010, Sham Intravitreal Injection; Biological · Device
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Dry Eye Disease
Interventions: Lotemax, Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears), In Vivo Confocal Microscopy (IVCM); Drug · Diagnostic Test
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma
Interventions: rituximab, bendamustine hydrochloride, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 204
States / cities: Duarte, California • Aurora, Colorado • Boulder, Colorado + 142 more

Conditions: Schizophrenia
Interventions: D-cycloserine, Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
Interventions: OnabotulinumtoxinA 100 UNT [Botox]; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Orange, California

Conditions: Type 1 Diabetes
Interventions: Sitagliptin, Sugar Pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

Airway Muscle Training for Obstructive Sleep Apnea

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis

Wolman/CESD Natural History Chart Review and Longitudinal Follow-Up

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Laser 360iQ: Optimal Light-laser Combination Therapy

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

Measurement of Angiogenic Related Growth Factors in Urine and Blood From Patients With Pulmonary Vein Stenosis

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Functional Organization of the Superior Temporal Gyrus for Speech Perception

DKA Optic Ultrasound

A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes